Abstract
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Current Drug Targets
Title: Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Volume: 1 Issue: 3
Author(s): M. A. Khan, R. C. Calvert, M. E. Sullivan, C. S. Thomson, F. H. Mumtaz, R. J. Morgan and D. P. Mikhailidis
Affiliation:
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Abstract: Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Export Options
About this article
Cite this article as:
Khan A. M., Calvert C. R., Sullivan E. M., Thomson S. C., Mumtaz H. F., Morgan J. R. and Mikhailidis P. D., Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists, Current Drug Targets 2000; 1 (3) . https://dx.doi.org/10.2174/1389450003349164
DOI https://dx.doi.org/10.2174/1389450003349164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Emerging Trends On Drug Delivery Strategy of Momordica charantia against Diabetes and its Complications
Current Drug Delivery Does Pharmacological Therapy Still Play a Role in Preventing Sudden Death in Surgically Treated Tetralogy of Fallot?
Mini-Reviews in Medicinal Chemistry Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction
Current Hypertension Reviews Statins: Are They All the Same?
Current Drug Therapy Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Current Psychiatry Reviews Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Current Vascular Pharmacology Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets The Effects of Italian Mediterranean Organic Diet (IMOD) on Health Status
Current Pharmaceutical Design